Teacher Retirement System of Texas Sells 122,066 Shares of Abbott Laboratories $ABT

Teacher Retirement System of Texas reduced its position in shares of Abbott Laboratories (NYSE:ABT) by 20.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 478,986 shares of the healthcare product maker’s stock after selling 122,066 shares during the quarter. Teacher Retirement System of Texas’ holdings in Abbott Laboratories were worth $64,155,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Norges Bank purchased a new stake in Abbott Laboratories during the second quarter valued at approximately $3,026,180,000. Laurel Wealth Advisors LLC increased its stake in shares of Abbott Laboratories by 13,347.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after purchasing an additional 6,011,891 shares in the last quarter. Vanguard Group Inc. raised its holdings in Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after purchasing an additional 2,977,715 shares during the period. First Trust Advisors LP lifted its position in Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after purchasing an additional 1,972,097 shares in the last quarter. Finally, TD Asset Management Inc grew its holdings in Abbott Laboratories by 98.6% during the second quarter. TD Asset Management Inc now owns 3,467,896 shares of the healthcare product maker’s stock valued at $471,669,000 after purchasing an additional 1,721,523 shares during the period. Institutional investors own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Med‑tech strength and margin expansion: Abbott said its Devices/MedTech businesses performed well in Q4 and reported adjusted EPS growth of ~12%, which supports longer‑term earnings power. Abbott Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Analyst support and income profile: Many sell‑side analysts maintain buy/outperform ratings and above‑current price targets, and the company’s Dividend‑King status and buyback capacity are cited as reasons some investors view the recent pullback as a buying opportunity. Is Abbott’s January Pullback a Good Time to Buy?
• Neutral Sentiment: Q4 EPS matched consensus: Abbott reported adjusted EPS of $1.50, in line with estimates — a neutral datapoint that limits the positive surprise potential. Abbott (ABT) Matches Q4 Earnings Estimates
• Negative Sentiment: Revenue miss and segment weakness: Total Q4 revenue of $11.46B fell short of Street estimates (~$11.8B). Weakness in Diagnostics (volatile post‑COVID testing) and a ~9% decline in Nutrition weighed on top‑line growth, prompting investor concern. Abbott misses quarterly revenue estimates on weakness in diagnostics segment
• Negative Sentiment: Guidance disappointed modestly: Q1 EPS guidance (1.12–1.18) is below consensus (~1.20) and FY adjusted EPS range (5.55–5.80) leaves limited upside vs. Street forecasts, which amplified the sell‑off after results. Abbott Reports Fourth-Quarter and Full-Year 2025 Results
• Negative Sentiment: Regulatory/legal risk in India: Documents show scrutiny of an Abbott Healthcare (India) supply chain tied to alleged misuse of a codeine‑based cough syrup — a developing regulatory issue that adds uncertainty and headline risk. Abbott faces India scrutiny in cough syrup abuse investigation, documents show
• Negative Sentiment: Options flow and investor positioning: There was a large uptick in put buying (≈80.6k puts), indicating elevated bearish bets or hedging demand that can accelerate downside during news flows. (trade flow reported by market sources)

Analyst Upgrades and Downgrades

ABT has been the topic of a number of analyst reports. Jefferies Financial Group lifted their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Sanford C. Bernstein increased their price objective on shares of Abbott Laboratories from $150.00 to $154.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating for the company in a report on Friday, January 9th. Royal Bank Of Canada restated an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 16th. Finally, William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $146.56.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $108.50 on Friday. The firm has a market cap of $188.67 billion, a PE ratio of 13.60, a PEG ratio of 2.00 and a beta of 0.72. The stock has a 50 day moving average of $125.23 and a 200 day moving average of $128.54. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12 month low of $105.78 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the business posted $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s payout ratio is presently 31.58%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.